HQL (abrdn Life Sciences Investors) Total Stockholders Equity: $560.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $22.08
GF Value $62.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors Total Stockholders Equity?

abrdn Life Sciences Investors HQL -2.60% 51 Total Stockholders Equity is $560.8 Mil as of Mar. 2026. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review.

abrdn Life Sciences Investors's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $560.8 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. abrdn Life Sciences Investors's Book Value per Share for the quarter that ended in Mar. 2026 was $18.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. abrdn Life Sciences Investors's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

abrdn Life Sciences Investors  (NYSE:HQL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

abrdn Life Sciences Investors's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(560.827-0)/30.408
=18.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

abrdn Life Sciences Investors's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 560.827
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors Total Stockholders Equity Related Terms

abrdn Life Sciences Investors Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for abrdn Life Sciences Investors's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors Total Stockholders Equity Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 523.44 397.90 401.93 459.70 513.66

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 441.07 459.70 395.94 513.66 560.83
HQL
51GF Score
abrdn Life Sciences Investors HQL
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $560.8 Mil mean?
abrdn Life Sciences Investors (HQL) has a Total Stockholders Equity of $560.8 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for abrdn Life Sciences Investors and its competitors.
Is abrdn Life Sciences Investors' Total Stockholders Equity too high?
abrdn Life Sciences Investors' current Total Stockholders Equity is $560.8 Mil. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Total Stockholders Equity compare to IIM and NOAH?
abrdn Life Sciences Investors' Total Stockholders Equity of $560.8 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for an Asset Management company?
A good Total Stockholders Equity depends on the Asset Management industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for abrdn Life Sciences Investors and its competitors. abrdn Life Sciences Investors's current Total Stockholders Equity is $560.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.08 — trading 64.4% below its estimated fair value. The current Total Stockholders Equity is $560.8 Mil. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Total Stockholders Equity is $560.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $22.08 is trading 64.4% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • Total Stockholders Equity: $560.8 Mil
  • GF Value™: $62.01 vs. price of $22.08 (64.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.08
Price
$62.01
GF Value